Alteogen’s Hybrozyme™ platform continues to expand its global footprint, securing major licensing deals with Merck, AstraZeneca, and Daiichi Sankyo.

Drivers such as dosing-convenience, IRA price-negotiation avoidance, and biosimilar defense reinforce sustained demand for SC-conversion technology.

With Keytruda Qlex SC launch, expected milestones, additional tech-out deals, and a potential KOSPI transfer in 2026, investment momentum remains strong.